Shimoni, Yakhin, and Xiu-Fang Liu. Role of PKC in autocrine regulation of rat ventricular K ϩ currents by angiotensin and endothelin. Am J Physiol Heart Circ Physiol 284: H1168-H1181, 2003 10.1152 10. /ajpheart.00748.2002 and sustained K ϩ currents were measured in isolated rat ventricular myocytes obtained from control, steptozotocin-induced (Type 1) diabetic, and hypothyroid rats. Both currents, attenuated by the endocrine abnormalities, were significantly augmented by in vitro incubation (Ͼ6 h) with the angiotensin-converting enzyme inhibitor quinapril or the angiotensin II (ANG II) receptor blocker saralasin. Western blots indicated a parallel increase in Kv4.2 and Kv1.2, channel proteins that underlie the transient and (part of the) sustained currents. Under diabetic and hypothyroid conditions, both currents were also augmented by an endothelin receptor blocker (PD142893) or by an endothelin-converting enzyme inhibitor. Kv4.2 density was also enhanced by PD142893. Incubation (Ͼ5 h) with the PKC inhibitor bisindolylmaleimide augmented both currents, whereas the PKC activator dioctanoyl-rac-glycerol (DiC8) prevented the augmentation of currents by quinapril. DiC8 also prevented the augmentation of Kv4.2 density by quinapril. Specific peptides that activate PKC translocation indicated that PKC-⑀ and not PKC-␦ is involved in ANG II action on these currents. In control myocytes, quinapril and PD142893 augmented the sustained late current but had no effect on peak current. It is concluded that an autocrine release of angiotensin and endothelin in diabetic and hypothyroid conditions attenuates K ϩ currents by suppressing the synthesis of some K ϩ channel proteins, with the effects mediated at least partially by PKC-⑀. diabetes; protein kinase C WE HAVE RECENTLY ESTABLISHED that an autocrine release of angiotensin II (ANG II) plays a central role in attenuating a transient and a sustained K ϩ current in single myocytes isolated from (Type 1) diabetic rats (45). The in vitro blockade of ANG II action or formation (for Ͼ5 h) augments both currents. This effect is blocked by cycloheximide, suggesting that new protein synthesis mediates current augmentation after removal of ANG II-related current inhibition.
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Several additional issues relating to the autocrine/ paracrine control of ion channels arise from the preceding work. ANG II has multiple and diverse cellular actions (11) . A key modulator of cellular function, protein kinase C (PKC), is a major target of ANG II (11) . PKC is activated in diabetes, with several isoforms affected (22, 29) . The ⑀-isoform of PKC is of particular interest, because it is involved in several cardiac pathologies and plays a key role in cardioprotection (10) . Furthermore, PKC-⑀ also interacts with K ϩ channels (33, 44) . Diabetes leads to a change in the subcellular distribution of PKC-⑀, so that a greater proportion is found in membrane fractions (29) . This is prevented by ANG II receptor blockade (29) . The acute effects of PKC-⑀ activation on K ϩ currents are altered in diabetes as well (44) . Alterations in K ϩ currents can lead to severe cardiac arrhythmias (19, 27, 48) . Thus it is of importance to establish some of the mediating mechanisms, such as whether the suppression of the two K ϩ currents by ANG II is associated with PKC-⑀ activation and translocation.
Other pathological conditions that are associated with PKC-⑀ activation and subcellular translocation also result in attenuated K ϩ currents. These include hypoxia and ischemia (16) as well as cardiac hypertrophy (17) . The same transient and sustained currents are attenuated in ventricular myocytes from hypothyroid rats (46) , in which PKC-⑀ is also activated (42) . It was thus of interest to establish whether ANG II is also a mediator of K ϩ current suppression under conditions other than diabetes. Finally, there have been reports indicating that after stress there is enhanced production and/or release of other autocrine/paracrine agents in the heart. For example, endothelin (ET)-1 is released (12), possibly from cardiac myocytes as well as from other cell types (41) .
The aims of this study were therefore to extend earlier work and establish the following: 1) Does restoration of current magnitudes after ANG II blockade involve the synthesis of new channels? 2) Does autocrine/paracrine regulation of K ϩ currents occur in other pathologies such as under hypothyroid conditions? 3) Do other agents such as ET-1 play a role in the chronic suppression of K ϩ currents? 4) Is PKC-⑀ involved in the chronic suppression of K ϩ currents and, more specifically, does the restoration of current magnitudes involve a return of PKC distribution to the normal (prediabetic, euthyroid) state?
The present work suggests that the answer to all of these questions is affirmative.
METHODS
All of the experiments were done according to guidelines established and approved by the Animal Care Committee of the University of Calgary. Rats were anesthetized by methoxyflurane or CO 2 inhalation and killed by cervical dislocation. Hearts were removed, and the aortas were cannulated for coronary perfusion on a Langendorff apparatus.
Animals. Ventricular cells or tissue were obtained from three groups of adult Sprague-Dawley male rats (200-300 g): untreated control rats, rats made diabetic with a single intravenous injection of streptozotocin (100 mg/kg) 8-14 days before the experiments, and rats made hypothyroid by thyroidectomy 4-5 wk before the experiments.
Cell isolation. Current recordings were done using isolated cells from the free wall of the right ventricle, obtained by enzymatic dispersion using collagenase (Yakult; Tokyo, Japan) and protease (Sigma type XIV). Details can be found in an earlier publication (44) .
Current recordings. These were done using the whole cell suction electrode method. Low-resistance electrodes (2-4 M⍀) were used to minimize series resistance, which was also compensated for electronically. Pipette solutions contained (in mM) 120 K-aspartate, 30 KCl, 4 Na 2ATP, 10 EGTA, 1 CaCl2, 1 MgCl2, and 10 HEPES (pH brought to7.2 with KOH). The perfusing solution contained (in mM) 150 NaCl, 5.4 KCl, 1 CaCl 2, 1 MgCl2, 5.5 glucose, 5 HEPES, and 0.3 CdCl2 to block L-type Ca 2ϩ current. Two currents were recorded: the calcium-independent transient outward current (34) and a sustained delayed rectifier current. The transient current was measured as the peak outward current (I peak) and not as the difference between the peak and steady-state currents, because the steady-state current was also subject to differential changes in these experiments. The sustained current activates considerably slower than I peak (4) and was measured at the end of 500-ms pulses, at which time Ipeak is completely inactivated. The late current is referred to as Ilate. Recent analysis by Himmel et al. (21) has shown that a mixture of four currents is present in rat ventricular myocytes, and the effects of the angiotensin-converting enzyme (ACE) inhibitor quinapril were analyzed in detail using their methods (see below) to establish which components are affected.
Data analysis. Currents were recorded at 20-22°C (digitized at 2 kHz using a DT2821 analog-to-digital board) and stored for subsequent analysis. Cell capacitance was measured for each cell by integrating current traces (digitized at 10 kHz) obtained in response to 5-mV steps from a holding potential of Ϫ80 mV. Dividing current magnitudes by capacitance gave current densities.
To account for some variation in the diabetic state between rats, currents were measured in untreated myocytes on each experimental day as well as in myocytes from treated groups (giving slightly different baselines for each protocol). The current densities in cells from each experimental group were averaged and compared. Measurements were made in all cells at ϩ50 mV, at which the fast sodium current is negligible, and at Ϫ110 mV. In many cells, full current-voltage relationships were also obtained.
Earlier work by Himmel et al. (21) provided a comprehensive analysis of the different current components by analyzing the inactivation characteristics of total outward currents in rat ventricular cells. They showed that a protocol consisting of 2,000-ms prepulses to potentials ranging from Ϫ140 to ϩ20 mV (in 10-mV steps except for the range of Ϫ60 and Ϫ20 mV, in which 5-mV steps were used), followed by test pulses to ϩ60 mV, allowed the measurement of steady-state inactivation of currents that could best be fit by two Boltzmann functions. The normalized currents [current (I)/maximal current (Imax)] were fit to the equation
where a and b are the relative contributions of the two functions and r is a residual component.
The inactivation process was analyzed separately for Ipeak and Ilate at the end of the test pulse [see Himmel et al. (21) ]. This analysis revealed the presence of four current components. The parameters a and b (for Ipeak) obtained by this analysis corresponded to a delayed rectifier and a transient current, respectively, whereas r reflected a noninactivating current. Vm is membrane potential, V0.5 is the half-inactivation potential, and k is the slope factor (separate for each function).
Reagents. Saralasin was obtained from Calbiochem, and PD142893 and the ET-converting enzyme (ECE) inhibitor (fragment 16-38 of Big ET-1) were from Sigma. Quinapril was a gift from Dr. A. Gillis (Foothills Hospital, Calgary, Alberta, Canada). The PKC-related peptides were obtained from Dr. D. Mochly-Rosen, Stanford University.
Western blotting. The channel proteins encoded by Kv4.2 and Kv4.3 underlie the transient outward current in rat ventricular cells (14, 34) . The sustained current has several components (21) and is the complex expression of several channel proteins (34) . In our experiments, antibodies directed against Kv4.2, Kv1.2 (Alomone), and Kv4.3 (Alomone and an antibody kindly provided by Dr. J. Nerbonne) were used. We were able to obtain consistent and reliable data using the Kv4.2 and Kv1.2 antibodies. However, both antibodies directed against Kv4.3 gave bands of poorer quality, and the results could not be used. However, the results with the Kv4.2 and Kv1.2 antibodies were sufficient to establish that current changes are paralleled by changes in protein density (see below).
The membrane fractions of ventricular tissue (rather than cells) were used to obtain sufficient protein (see DISCUSSION) . Because many of the effects observed on current magnitudes were only seen after 6 h, the following procedure was followed: aortas were cannulated, and the hearts were perfused using a Langendorff apparatus (at 37°C, 70 cmH2O pressure) for at least 7 h in the absence or presence of different compounds, as indicated below. After 7-9 h, during which the hearts maintained rhythmic spontaneous beating, both ventricles were dissected and frozen rapidly for subsequent analysis.
The ventricles were later thawed and (ϳ0.4 g tissue) homogenized in Dounce [on ice in a 10 mM Tris buffer containing 0.5 M sucrose and a protease inhibitor tablet (Roche)]. The homogenate was centrifuged at 4°C for 15 min at 1,200 rpm to remove debris and nuclei. The supernatant was removed and spun at 100,000 g for 1 h. The membrane pellet was resuspended in Tris buffer containing 1% Triton X-100. Trituration and vigorous vortexing were used to resuspend the pellet until large particles were no longer visible. Protein concentration in the membrane fraction was determined (using duplicates for each sample) by the bicinchoninic acid assay (Pierce). Membrane proteins (including positive and negative controls, see below) were separated by 10% acrylamide SDS-PAGE and transferred to 0.45 M nitrocellulose membranes before being blocked with 5% nonfat dried milk in a Tris-buffered saline (TBS) solution. Membranes were labeled with rabbit polyclonal anti-Kv4.2 or Kv1.2 (diluted 1:400), washed with TBS solution, and probed with 1:4,000 horseradish peroxidase-conjugated goat anti-rabbit IgG. Detection was achieved with a chemiluminescent substrate (Pierce) using Biomax film.
Quantification of Kv4.2 and Kv1.2. SDS-PAGE gels used for transfer to nitrocellulose and Western blotting were run simultaneously with gels loaded with 100 g protein and stained with Coomassie brilliant blue R-250 (Bio-Rad). Densitometry was performed on the immunoreactive bands as well as on an arbitrary band on the Coomassie blue protein gels to quantitatively normalize to protein loading levels in all lanes. A Sharp JX-330 Scanner and Image Master 1D Software (Pharmacia Biotech) were used. Each gel had two to three samples from each experimental group, which allowed for variations in optical density (OD) due to variations in film development. Channel protein in the different groups (in OD units) was normalized to the OD of the Coomassie blue band or to protein loading levels (100 g protein) and averaged for the different groups. Both methods of normalization gave similar results.
To verify the identification of the correct bands on the gel corresponding to Kv4.2, incubation of samples was also performed in the presence of competing peptides. This eliminated the band for Kv4.2, but other bands were also blocked (see below and Fig. 2) . A more rigorous control test was therefore used. Human embryonic kidney (HEK-293) cells were transfected with cDNA for Kv4.2 using a pIRES-ht GFP-1a vector. After protein expression, cells were homogenized, and human embryonic kidney cell membrane extracts were assayed for Kv.4.2 alongside the ventricular samples. The Kv4.2 bands from the HEK-293 cells were located in parallel to the bands from ventricular tissue, confirming the identity of the bands from the ventricular samples (Fig. 2) . The identity of the Kv1.2 band was confirmed using a competing peptide (see below).
Statistics. An unpaired Student's t-test or (mostly) ANOVA with a Student-Newman-Keuls multiple-comparison post hoc test were used to establish whether experimental groups differed (with P Ͻ 0.05 indicating a significant difference).
RESULTS
The first set of results, summarizing and extending earlier work, demonstrates that the exposure of myocytes from diabetic rats to the ACE inhibitor quinapril for 6 h or longer augments the peak (transient) and late outward currents. Figure 1 shows sample current traces (A) as well as the full current-voltage relationships (B) for I peak (left) and I late (right). Mean (ϮSE) current densities are plotted against membrane potentials in the absence and presence of quinapril (6-to 9-h incubation). I peak was significantly augmented by quinapril (P Ͻ 0.0005 for membrane potentials between Ϫ30 and ϩ50 mV). I late in this potential range was also significantly enhanced (P Ͻ 0.005). There were no effects of quinapril on I late in the negative potential range (Ϫ50 to Ϫ110 mV), in which the inward rectifying background current is activated. Fig. 1 . Effects of an angiotensin-converting enzyme (ACE) inhibitor on K ϩ currents in ventricular myocytes from diabetic rats. A: sample current traces obtained in myocytes from a diabetic rat in response to 500-ms depolarizing steps from Ϫ80 mV to membrane potentials ranging from 0 to ϩ50 mV. Left, traces in an untreated cell; right, membrane potentials in a cell exposed to 1 M quinapril for 7 h. The line on the left indicates the zero-current level. B: current-voltage relationships showing the mean (ϮSE) densities for peak currents (Ipeak; left) and late currents (Ilate; right) in the absence of quinapril (circles) or after 6-9 h in 1 M quinapril (squares). The differences for both currents were highly significant between Ϫ30 and ϩ50 mV (P Ͻ 0.0005 for Ipeak; P Ͻ 0.005 for Ilate).
We subsequently attempted to analyze more precisely which current components are modulated by quinapril. We repeated the analysis of Himmel et al. (21) and analyzed the inactivation of the total outward currents. Prepulses (2,000 ms) were given to potentials ranging from Ϫ140 to Ϫ20 mV in 10-mV steps (5-mV steps between Ϫ60 and Ϫ20 mV), followed by a 500-ms pulse to ϩ50 mV. Current amplitudes were normalized to maximal currents, and the data were fit to a sum of two Boltzmann functions with the residual component r. The analysis was done separately for I peak and I late at the end of the test pulses. The different parameters (see METHODS for the equation) were compared in cells from diabetic rats in the absence (n ϭ 25) or presence (n ϭ 21) of quinapril (6-9 h). The mean and SE values, shown in Table 1 , show that both a and b (for I peak ) are significantly augmented by quinapril, with no effect on the residual current r or on half-inactivation voltages. The slope factor k was also unchanged (not shown for clarity). This suggests that both a transient and a delayed rectifier current are enhanced by ACE inhibition. We then proceeded to investigate whether this could be correlated to an augmentation in the expression of proteins underlying these currents.
The increase in current magnitude was shown earlier to be sensitive to cycloheximide, suggesting that protein synthesis is involved. The transient outward current in rat ventricular cells is associated with the channel proteins Kv4.2 and Kv4.3 (14, 18, 34) . The molecular correlate of I late is unclear and is presumed to be a mixture of several isoforms, including Kv1.2 (34).
Nishiyama et al. (35) reported that under diabetic conditions, there is a decrease in Kv4.2 message and protein levels. Interestingly, hypothyroid conditions also resulted in a reduction in message levels of Kv4.2 (36). Qin et al. (39) also showed a reduction in message and protein levels of Kv4.2 in diabetic conditions. These changes in Kv4.2 presumably underlie the attenuation in the transient outward current in diabetic and hypothyroid conditions (26, 46) .
We set out to establish whether the augmentation in I peak by the ACE inhibitor quinapril is paralleled by an increase in Kv4.2. We performed Western blots on homogenized ventricular tissue obtained from hearts perfused for 7-9 h. We used control and diabetic rat hearts, with the latter divided into untreated hearts and hearts perfused with 1 M quinapril. We confirmed that Kv4.2 density is attenuated under our experimental conditions as well, although in this group the reduction in Kv4.2 density in diabetic hearts was not significant. Nevertheless, Kv4.2 protein in diabetic hearts was significantly (P Ͻ 0.03) augmented after perfusion with quinapril compared with untreated diabetic hearts. Figure 2 , top left, shows sample blots showing results from the three experimental groups. HEK-293 cells, transfected with cDNA for Kv4.2, were also used as a control to ensure the correct identification of the band corresponding to Kv4.2. A further control was obtained by incubating tissue with the peptide used to generate the antibody. This eliminated the signal at the appropriate location on the gels (Fig.  2, top right) . Densitometry scans of the gels were used to quantify the signals, with the mean (ϮSE) data (normalized OD) shown in Fig. 2 , bottom.
This result shows that the augmentation of the transient outward current, which occurs after a reduction in the formation of angiotensin, is associated with an enhanced synthesis of Kv4.2 channels.
Western blot using the Kv1.2 antibody showed that this protein is reduced in diabetic hearts compared with control and, more importantly, that Kv1.2 is significantly (P Ͻ 0.02) augmented after 6-9 h in quinapril. This result is shown in Fig. 3 . Blotting with this antibody consistently gave two bands, which may represent two forms of the channel (e.g., one phosphorylated). The identity of the band for Kv1.2 (used in densitometry) was confirmed in a control experiment using the competing peptide. This abolished the lower of the two bands, as shown in Fig. 3 .
The results with Western blot show that the increase in transient and sustained (late) currents is paralleled by an increase in channel protein density. These results correlate to the increase we found in parameters a and b (for the early current) in the inactivation process (see above) and thus provide strong validation for the analysis of Himmel et al. (21) , who suggested that a and (early) b correspond to a sustained and a transient current, respectively.
Hypothyroid conditions. Because the local cardiac renin-angiotensin system is activated in a variety of pathological conditions (11), we proceeded to examine whether similar effects could be demonstrated in situ- Values are means Ϯ SE; n ϭ 25 cells from diabetic rats in the absence of quinapril and 21 cells from diabetic rats after 6-9 h in quinapril. See METHODS for the equation. Analysis of inactivation was performed separately for the early (peak) and late currents. Parameter a reflects a delayed rectifier current, whereas parameter b for the peak current reflects a transient current, as suggested by Himmel et al. (21) . Both of these were significantly (* P Ͻ 0.02 for a and † P Ͻ 0.0002 for b) augmented by quinapril. Residual current r, half-inactivation voltages (V0.5), and slope factors (not shown for clarify) were unchanged by quinapril. Parameter b for the late current, presumed to represent an additional small outward current, was also unchanged. ations other than diabetes. We have previously extensively studied the effects of altered thyroid status on the same K ϩ currents, demonstrating a reduction in both transient and sustained currents in hypothyroid conditions (46) . Thus, in the next set of experiments, we studied whether ACE inhibition could restore the attenuated currents in myocytes from hypothyroid rats, as is the case in diabetic conditions. Similar protocols were followed, with exposure of myocytes to 1 M quinapril for 6 h or longer. This procedure significantly enhanced both the transient and sustained outward currents, measured at ϩ50 mV. Quinapril increased I peak from 15.3 Ϯ 0.8 (40 cells) to 19.7 Ϯ 1.0 (47 cells) pA/pF (P Ͻ 0.003) and I late from 5.9 Ϯ 0.3 to 7.3 Ϯ 0.3 pA/pF (means Ϯ SE, P Ͻ 0.003).
Current-voltage relationships were plotted showing a significant (P Ͻ 0.03 to P Ͻ 0.0003) enhancement of I peak between 0 and 50 mV. I late was significantly (P Ͻ 0.002) enhanced between Ϫ30 and ϩ50 mV. Figure 4 shows these results. Sample current traces are shown in Fig. 4A , and the current-voltage relationships for I peak and I late are shown in Fig. 4B .
Western blots of ventricular tissue from hypothyroid rats showed a marked and significant (P Ͻ 0.007) reduction in Kv4.2. This corresponds to the reduction in mRNA levels for Kv4.2 in hypothyroid rat ventricles, as reported by Nishiyama et al. (36) . Importantly, the perfusion of hearts from hypothyroid rats for 6 h or longer with 1 M quinapril produced a clear and significant (P Ͻ 0.006) increase in the density of Kv4.2. A sample blot is shown in Fig. 5A . Figure 5B shows the mean (ϮSE) ODs (normalized to protein loading levels) obtained by densitometry in the three groups.
To conclude thus far, the results point to a mechanism common to both diabetes and hypothyroid conditions, whereby local ANG II levels are increased, with a consequent suppression of outward K ϩ currents. The Kv4.2 component appears to be downregulated. Blocking ANG II formation augments both the transient current and Kv4.2 density.
Involvement of ET-1. We next examined whether other autocrine/paracrine factors could be implicated in suppressing the two K ϩ currents in the diabetic and hypothyroid states. Of particular interest was the pep- The right shows that incubation with the control peptide used to generate the antibodies (4 blank lanes) prevents labeling of the band that corresponds to Kv4.2 (although other bands were also blocked). In each gel, extracts from 2 different rats are shown for each group. Bottom: summary data obtained by densitometry. Optical density (OD)/100 g protein is plotted for the 3 groups, showing that in STZ-treated rats there is a significant (* P Ͻ 0.03) increase in Kv4.2 density after quinapril treatment. OD normalized to scanned bands on Coomassie blue-stained gels gave similar results.
tide ET-1. This peptide, which may be involved in cardioprotection and/or arrhythmogenesis, is released in the heart under conditions of stress (12, 41) . Importantly, there is evidence that ET-1 is released from the myocytes themselves (1, 23) . ET-1 was also of particular interest because among its multiple actions is the suppression of several K ϩ currents in rat and human ventricular myocytes (7, 24, 28 ; see also DISCUSSION) as well as an activation and selective translocation of PKC-⑀ (25, 43, 47) .
Using the same rationale as with ANG II, we hypothesized that if ET-1 is released from the isolated myocytes and causes current suppression, then a receptor inhibitor might abolish this effect. In the next set of experiments, myocytes were exposed to the nonselective ET-1 receptor blocker PD142893 (0.5 M) for 6 h or longer. The blockade of ET-1 receptors in myocytes from diabetic rats led to a significant enhancement of both I peak and I late . In these experiments, I peak (at ϩ50 mV) was enhanced from 16.2 Ϯ 0.7 (n ϭ 70) to 20.0 Ϯ 0.7 pA/pF (n ϭ 68, P Ͻ 0.0004), whereas I late was augmented from 5.8 Ϯ 0.2 to 7.3 Ϯ 0.3 pA/pF (P Ͻ 0.0004). In a smaller number of cells, current-voltage relationships were obtained. I peak was significantly augmented by PD142893 between Ϫ40 (P Ͻ 0.05) and ϩ50 mV (P Ͻ 0.0001). I late was significantly elevated between Ϫ30 (P Ͻ 0.04) and ϩ50 mV (P Ͻ 0.002). These results are shown in Fig. 6 .
Myocytes from hypothyroid rats were also incubated with the ET-1 receptor blocker. Exposure to 0.5 M PD142893 for Ͼ6 h caused an increase in I late from 6.0 Ϯ 0.2 (n ϭ 60) to 7.91 Ϯ 0.9 pA/pF (n ϭ 56, P Ͻ 0.0002). The increase in I peak was from 18.0 Ϯ 0.9 to 21.6 Ϯ 1.6 pA/pF (P Ͻ 0.05). These results (not shown) suggest that in both diabetes and under hypothyroid conditions, there is a tonic release of ET-1 from cardiac myocytes, which contributes to K ϩ current attenuation. Fig. 3 . Western blot using an antibody directed against Kv1.2. Top: gels with the band for Kv1.2 using cardiac extracts from control (C) rats, STZ-treated rats, and STZ-treated rats after perfusion for 8-9 h with 1 M quinapril (Quin). Two bands were labeled by this antibody, but the competing peptide only blocked the lower one, as shown in the two lanes on the right. Extracts from 2 control rats in the absence and presence of the peptide identify the lower band as corresponding to Kv1.2. Bottom: mean Ϯ SE values of the OD (normalized to an arbitrary band on a Coomassie blue-stained gel with the same samples). Kv1.2 is significantly decreased in diabetic hearts, but quinapril significantly enhances the abundance of this protein. * P Ͻ 0.05. Fig. 4 . Effects of an ACE inhibitor on K ϩ currents in myocytes from hypothyroid rats. A: sample current traces obtained in response to pulses from Ϫ80 mV to potentials ranging from 0 to ϩ50 mV in the absence of quinapril (left) or after 6.5 h in 1 M quinapril (right). B: current-voltage relationships for Ipeak (left) and Ilate (right) in the absence of quinapril (F; n ϭ 27) or after 6-9 h in 1 M quinapril (s; n ϭ 32). Mean (ϮSE) current densities are shown. For Ipeak, the differences were significant (P Ͻ 0.003) between Ϫ30 and ϩ50 mV (asterisks left out for clarity). For Ilate, the differences were significant (P Ͻ 0.003) between Ϫ20 and ϩ50 mV.
In further experiments, we tested whether blocking the formation of ET-1 by inhibition of ECE would also lead to current augmentation. Cells from diabetic rats were incubated (6-8 h) in 5 M of a peptide fragment of Big ET-1 (16-38) that has been shown to block ECE (32, 51) . The inhibition of ECE led to a marked and significant enhancement of both currents. At ϩ50 mV, I peak was enhanced from 14.8 Ϯ 1.3 (n ϭ 35) to 18.8 Ϯ 1.1 pA/pF (n ϭ 36, P Ͻ 0.025), whereas I late was enhanced from 4.9 Ϯ 0.2 to 7.2 Ϯ 0.3 pA/pF (P Ͻ 0.0001). Sample current traces and the current-voltage relationships are shown in Fig. 7 .
Thus blockading either the formation or binding of ET-1 leads to current augmentation, strongly supporting the suggestion that ET-1 is released by the myocytes, with a consequent suppression of these K ϩ currents. We subsequently tested whether the enhancement of the transient current could be related to an increase in channel protein.
Hearts from thyroidectomized rats were perfused for 7-8 h with either control solution (n ϭ 6) or the ET-1 receptor blocker PD142893 (0.27 M, n ϭ 7). Western blots from membrane extracts from these hearts were used to assay the level of Kv4.2. As shown in Fig. 8 , the blocking of ET-1 receptors led to a significant (P Ͻ 0.04) enhancement of Kv4.2 density.
Involvement of PKC. We subsequently attempted to gain further insight into the cellular mechanisms involved in these autocrine/paracrine effects. ANG II has a multitude of intracellular effectors (11) . One target of interest is PKC, which is a key regulator of many cellular functions (20) . It was hypothesized that if the activation of PKC by ANG II (or by ET-1) mediates the attenuation of the K ϩ currents under investigation, then exposure of cells to a PKC inhibitor would at least partially restore current density.
In the next set of experiments, myocytes from diabetic rats were exposed to the PKC inhibitor bisindolylmaleimide. After 6-9 h of incubation with this drug (100 nM), both I peak and I late were significantly (P Ͻ 0.002) augmented. The mean current density of I peak at ϩ50 mV was 17.3 Ϯ 0.8 pA/pF (n ϭ 51) in the absence of the PKC inhibitor and 21.7 Ϯ 1.1 pA/pF (n ϭ 36) after incubation with the PKC inhibitor. The corresponding values for I late were 5.0 Ϯ 0.2 and 7.2 Ϯ 0.4 pA/pF. These results are shown in Fig. 9 .
There are many isoforms of PKC, several of which are present in the adult rat ventricle (9) . Furthermore, both hypothyroid and diabetic conditions are associated with an activation of the ⑀-isoform of PKC (29, 42) . This is associated with subcellular redistribution, with a translocation from cytosol to membrane fractions (29, 43) . Interestingly, the inhibition of ANG II receptors was shown to prevent this redistribution in diabetic hearts (29) . We therefore sought to examine whether maintaining PKC-⑀ in an activated/translocated state would prevent the restoration of attenuated current magnitudes toward their normal values.
In these experiments, we used dioctanoyl-rac-glycerol (DiC8), a synthetic analog of diacylglycerol, the endogenous activator of (most isoforms of) PKC (20) . The incubation of cells with DiC8 was designed to maintain the activation and translocation of PKC despite the addition of the ACE inhibitor. When cells from diabetic rats were incubated with 20 M DiC8 for 1 h, followed by 1 M quinapril for Ͼ6 h (still in the presence of DiC8), the enhancement of I peak by quinapril was completely abolished, whereas the enhancement of I late was partially blocked. This result is shown in Fig. 10 . Figure 10A shows current traces obtained from cells in the absence of quinapril (left) or after exposure to quinapril (middle) as well as from a cell incubated with DiC8 and quinapril (right). Figure  10B shows the current-voltage relationships for these conditions, with mean (ϮSE) current densities shown for I peak (left) and I late (right). Note that DiC8 was completely effective in abolishing the effect of quinapril on I peak but was only partially effective in reducing the effect on I late .
Similar results were obtained with myocytes from hypothyroid rats. The current densities (at ϩ50 mV) for I peak in the absence of quinapril, after 6-9 h in quinapril, and after 6-9 h in quinapril and DiC8 were 17.1 Ϯ 1.1 (n ϭ 29) , 23.9 Ϯ 1.0 (n ϭ 28), and 17.9 Ϯ 1.1 . Current traces are in response to 500-ms pulses from Ϫ80 mV to potentials ranging from Ϫ20 to ϩ50 mV. B: current-voltage relationships for Ipeak (left) and Ilate (right) in the absence (F) or presence (s) of the ECE inhibitor. The effects of the ECE inhibitor were highly significant (P Ͻ 0.001) for both currents between Ϫ20 and ϩ50 mV.
pA/pF (n ϭ 25). The corresponding values for I late in these cells were 5.6 Ϯ 0.2, 8.2 Ϯ 0.2, and 5.9 Ϯ 0.3 pA/pF. The increase by quinapril was highly significant (ANOVA) for both currents (P Ͻ 0.001), as was the attenuation of currents by the combination of DiC8 and quinapril (P Ͻ 0.001). The attenuation of I late was more complete in cells from hypothyroid than diabetic rats. The reason for this is unclear at this stage.
We next considered whether the effect of maintained PKC activation/translocation on current magnitude was correlated to effects on channel protein. The experiments were repeated by perfusing hearts from hypothyroid and diabetic rats with quinapril alone (for Ͼ7 h) or with DiC8 for 0.5 h, followed by quinapril and DiC8 for Ͼ7 h. Subsequent Western blots using the Kv4.2 antibody showed that the enhancement of Kv4.2 density by quinapril (as shown in Figs. 2 and 5 ) was abolished when DiC8 was present. These results are shown in Fig. 11. Figure 11 , left, shows data from hypothyroid rats, and Fig. 11 , right, shows data from diabetic rats.
ANOVA showed that (for this small sample) the reduction of channel density was significant (P Ͻ 0.05) for diabetic hearts and was not quite significant (0.06 Ͻ P Ͻ 0.07) for hypothyroid rats. However, these results are completely consistent with the highly significant effects of this protocol on the K ϩ currents in diabetic and hypothyroid conditions. DiC8 may activate several PKC isoforms and may also have other PKC-independent effects as well (6) . To more specifically implicate the intracellular translocation of PKC-⑀, we took advantage of recent studies that have investigated the intracellular movement of PKC from its cytosolic to its membrane binding sites (31) . Specific peptides have been designed to activate or inhibit the translocation of specific PKC isoforms (10). In the following experiments, we incubated cells from diabetic rats with specific peptides linked to a carrier (antennapedia) that renders them membrane permeable (8) . We then added the ANG II receptor blocker saralasin, which was shown to augment I peak and I late (45) . Initially, we incubated cells with 1 M of a specific agonist of PKC-⑀ translocation (10) for 1 h. Saralasin was then added for Ͼ6 h, and currents were measured. As with quinapril and DiC8, the persistent activation of PKC translocation prevented the restoration of I peak Fig. 8 . Effects of blocking ET-1 receptors on the density of Kv4.2 in thyroidectomized rats. Top: Western blot using antibodies for Kv4.2 obtained from extracts from hearts perfused for Ͼ7 h. The bands are from a control rat, thyroidectomized rats, and thyroidectomized rats perfused with 0.27 M PD142893 (missing bands in middle were from a different protocol). Bottom: mean normalized (to a band on a Coomassie blue-stained gel) OD values in thyroidectomized rats in the absence (open bars; n ϭ 6) or presence (hatched bars; n ϭ 7) of 0.27 M PD142893. The density of Kv4.2 was significantly (* P Ͻ 0.04) enhanced by blocking ET-1 receptors. Fig. 9 . Effects of protein kinase C (PKC) inhibition on K ϩ currents in cells from STZ-induced diabetic rats. A: sample current traces in response to pulses ranging from Ϫ10 to ϩ50 mV shown in the absence of inhibitor (left) or after 7-h incubation with 100 nM bisindolylmaleimide, a PKC inhibitor. B: summary data of Ipeak (left) and Ilate (right) densities (at ϩ50 mV) in the absence of inhibitor and after 6-9 h with the PKC inhibitor. ** P Ͻ 0.005. Fig. 10 . Effects of quinapril in the presence of a diacylglycerol analog. A: current traces (in response to steps from Ϫ80 mV to potentials ranging from Ϫ10 to ϩ50 mV) obtained in cells from diabetic rats. The traces shown are from cells without quinapril (left), after 6 h in 1 M quinapril (middle), and after 6 h in quinapril and 20 M dioctanoyl-rac-glycerol (DiC8; added 1 h before quinapril; right). B: currentvoltage relationships for Ipeak (left) and Ilate (right) corresponding to the 3 experimental conditions. Mean Ϯ SE values are shown. DiC8 completely prevented the enhancement of the transient current by quinapril but only partially prevented the effect on Ilate. Fig. 11 . Enhancement of Kv4.2 density by ACE inhibition is blocked by PKC activation. Top left: Western blots with bands obtained from a control rat, 2 thyroidectomized rats, 3 thyroidectomized rats perfused with 1 M quinapril for Ͼ7 h, and 3 thyroidectomized rats perfused (7 h) with quinapril and 20 M DiC8 (added 30 min before quinapril). Right, bands from 2 STZ-induced diabetic rats, 3 STZ-induced diabetic rat hearts perfused with quinapril for 8-9 h, and 3 bands from diabetic hearts perfused with quinapril and DiC8. The augmentation of Kv4.2 density by quinapril in both hypothyroid and diabetic conditions is clearly blocked by DiC8; 100 g protein was loaded in all lanes. Bottom: summary data (means Ϯ SE), with band densities normalized to an arbitrary band on a Coomassie bluestained gel, obtained in parallel to the Western blot. Left, data from hypothyroid hearts (n ϭ 8, 0.06 Ͻ P Ͻ 0.07); right, data from diabetic hearts (n ϭ 3, P Ͻ 0.05).
and I late by saralasin. Figure 12 illustrates this result. Figure 12A shows current traces from diabetic myocytes exposed for 7 h to 1 M saralsin either in the absence (left) or presence of the PKC-⑀ agonist (right). Figure 12B shows the mean current densities at ϩ50 mV for I peak (left) and I late (right) in the absence (90 cells) and presence of saralasin with (85 cells) and without (86 cells) the PKC-⑀ agonist. The corresponding values for I peak are 18.6 Ϯ 0.8, 22.8 Ϯ 0.9, and 18.7 Ϯ 0.8 pA/pF and for I late are 6.0 Ϯ 0.2, 7.9 Ϯ 0.3, and 6.6 Ϯ 0.2 pA/pF. When PKC is maintained in its activated/translocated state, saralasin can no longer augment either current (P Ͻ 0.0003).
We also tested whether this effect was specific to the ⑀-isoform of PKC by incubating cells with the translocation agonist peptide specific for the ␦-isoform (10). The PKC-␦ translocation agonist peptide was added (1 M) to the incubation medium for 1 h, followed by 1 M saralasin for Ͼ6 h. In contrast to the PKC-⑀ translocation agonist peptide, the peptide specific for the ␦-isoform did not abolish the effects of saralasin. I peak and I late were both significantly (P Ͻ 0.0001) augmented by saralasin in the presence of this peptide. At ϩ50 mV, I peak increased from 13.5 Ϯ 1.0 (n ϭ 44) to 19.2 Ϯ 1.3 pA/pF (n ϭ 36), whereas I late increased from 4.7 Ϯ 0.2 to 6.5 Ϯ 0.3 pA/pF. A control dimer of the antennapedia carrier used to transport these peptides into the cells was also without effect, enabling saralasin to significantly (P Ͻ 0.0001) enhance I peak and I late . In this group, I peak was increased from 15.6 Ϯ 1.0 (n ϭ 32) to 21.8 Ϯ 1.2 pA/pF (n ϭ 27), and I late was increased from 5.6 Ϯ 0.2 to 7.6 Ϯ 0.3 pA/pF.
These results suggest that PKC-⑀ redistribution towards the normal prediabetic state is a prerequisite for K ϩ current augmentation.
Because ET-1 is also an activator of PKC (12), and of PKC-⑀ in particular (43, 47) , we also examined whether a maintained activation of PKC-⑀ with the translocation activator would prevent the enhancement of K ϩ currents by ET-1 receptor blockade. In this set of experiments, 0.5 M PD142893 (Ͼ6-h incubation) augmented I peak from 17.7 Ϯ 0.9 (n ϭ 47) to 21.6 Ϯ pA/pF (n ϭ 44, P Ͻ 0.05). However, when 1 M of the PKC-⑀ translocation activator was added 1 h before PD142893, this augmentation was blunted, with a mean density (at ϩ50 mV) of 18.1 Ϯ 0.9 pA/pF (n ϭ 44), which is significantly (P Ͻ 0.05) smaller than with PD142893 alone. The corresponding values for I late were 5.7 Ϯ 0.2, 7.5 Ϯ 0.4, and 7.0 Ϯ 0.3 pA/pF. As with ANG II, the augmentation of I late by ET-1 blockade is only slightly reduced by maintaining PKC in an activated state (see DISCUS-SION).
Control myocytes. It has been suggested that some of these autocrine/paracrine factors may be released under basal conditions, with an increase occurring under stress situations such as ischemia (12) . In the final set of experiments, we tested whether quinapril or PD142893 would affect these K ϩ currents in cells from control rats. We found that an exposure of 6-9 h of cells from control rats to either 1 M quinapril (21 cells) or 0.5 M PD142893 (23 cells) significantly augmented I late but had no effect on I peak . In control cells (n ϭ 24), the mean densities (at ϩ50 mV) for I peak and I late were 22.8 Ϯ 1.3 and 6.2 Ϯ 0.3 pA/pF, respectively. The corresponding values after ACE inhibition by quinapril were 20.1 Ϯ 1.5 (P Ͼ 0.05) and 7.3 Ϯ 0.3 pA/pF (P Ͻ 0.02). After exposure to the ET-1 receptor inhibitor, the mean densities were 21.3 Ϯ 2.1 (P Ͼ 0.05) and 7.4 Ϯ 0.2 pA/pF (P Ͻ 0.003). 
DISCUSSION
Summary of results. The results presented above provide several novel findings. Transient and sustained K ϩ currents in rat ventricular myocytes are attenuated under both diabetic and hypothyroid conditions. We showed previously that these currents are augmented after the inhibition of ANG II action or formation in diabetic conditions (Fig. 1) . We now show that this is the case in hypothyroid rats as well (Fig. 4) and demonstrate that the enhancement of the transient current involves an augmentation of Kv4.2, one of the channel proteins underlying this current (Figs. 2  and 5) . In diabetic conditions, we also showed (Fig. 3) that quinapril augments Kv1.2, which underlies some of I late in rat ventricular myocytes (34) . Furthermore, we found that under diabetic and hypothyroid conditions, an autocrine/paracrine release of ET-1 modulates these K ϩ currents. The in vitro blockade of ET-1 receptors or the inhibition of ET-1 formation in myoctes from diabetic or hypothyroid rats also leads to enhancement of these K ϩ currents (Figs. 6 and 7) associated with enhanced Kv4.2 protein (Fig. 8) . The results also show that part of the mechanism(s) mediating the changes in current density by both ANG II and ET-1 depend(s) on a subcellular redistribution of PKC-⑀. The attenuation of K ϩ currents is mediated by PKC activation, because a PKC inhibitor can reverse this attenuation (Fig. 9 ). This augmentation apparently depends on a recovery of PKC-⑀ distribution from the pathological toward the normal pattern (Figs. 10-12 ). Thus maintaining PKC-⑀ in an activated/translocated state prevents the enhancement of I peak by ANG II and ET-1 inhibition. The enhancement of I late is apparently less affected by PKC-related mechanisms than I peak . Further work is required to establish the contribution of Kv1.2 to the b component of voltagedependent inactivation of I peak .
Interpretation and significance. The simplest interpretation of these results is consistent with the reported activation of the local cardiac renin-angiotensin system (11) and the autocrine release of ANG II by the myocytes or a paracrine release from nonmyocytes. In parallel, or as a result of ANG II action (1, 23) , there is also an activation and autocrine/paracrine release of ET-1. Both ANG II and ET-1 contribute to suppression of the transient and sustained outward currents, the major repolarizing K ϩ currents in ventricular cells. The suppression of K ϩ currents by exogenous ET-1 when added acutely in vitro has been shown previously (7, 24) . We have shown (44) that an acute activation of PKC by DiC8, which normally suppresses K ϩ currents, does not have this action in diabetic and hypothyroid conditions, presumably because PKC is already activated in these pathologies. Thus acute actions of ET-1 released by autocrine mechanisms would presumably not be present (although this was not tested directly). Our present data suggest an endogenous chronic release under diabetic and hypothyroid conditions that attenuates currents at least partially by inhibiting synthesis of the channel ␣-subunits.
In combination, ANG II and ET-1 action on K ϩ currents will produce action potential prolongation (45) that may underlie the prolongation of the Q-T interval in the electrocardiogram, often recorded in diabetes and hypothyroidism (2, 15) . The restoration of current magnitudes takes several hours and depends on protein synthesis, with a concomitant increase of Kv4.2, a channel protein underlying the transient current. This suggests that ANG II and ET-1 repress the synthesis of (at least some of the) channel proteins underlying this current. When the autocrine action is blocked, channel protein synthesis can return to normal levels.
In addition, a key role for PKC-⑀ is suggested by the present work. When PKC-⑀ activation/translocation is maintained, the enhancement of I peak by ANG II or ET-1 blockade in both diabetic and hypothyroid conditions is abolished (Figs. 10 and 12) . However, the enhancement of I late is only partially affected by maintaining PKC activation. Kv4.2 enhancement by ACE inhibition is also prevented by PKC activation by DiC8 (Fig. 11) . The working hypothesis based on these results is that on activation, some of the translocation of PKC-⑀ is to the nucleus. PKC is involved in gene regulation by activation or binding of various transcription factors (20) . PKC-⑀ may thus directly suppress the synthesis of channel proteins underlying I peak but only some of the proteins underlying I late . There is abundant evidence showing that under diverse pathologies, there is an increase in PKC activation along with an attenuation of I peak . This occurs, for example, in cardiac hypertrophy (17, 30) , hypoxia (16), or hypothyroid conditions (42, 46) . The prevention of enhanced Kv4.2 synthesis by DiC8 does not positively confirm a causal connection between PKC activation and attenuation of channel synthesis, but this is a highly likely interpretation. It is of interest, however, that maintaining the activation of PKC only partially reverses the effects of ANG II and ET-1 inhibition on the noninactivating outward current (Fig. 10 and results with ET-1 blockade in the presence of the PKC-⑀ translocation activator). This implies that the enhancement of this current is achieved partially through a PKC-independent mechanism. Because the sustained outward current expresses a mixture of several channels (21, 34) , it is possible that the enhancement of one component of I late is PKC dependent, whereas others are augmented by a PKC-independent mechanism. The different protocols showed variability in the degree of suppression of I late by maintained PKC activation. This issue will require further investigation.
The results presented here are significant on several levels. First, they expand previous work on autocrine/ paracrine mechanisms in the heart, showing that multiple agents are released. It is presumed that these agents are released from the myocytes themselves, because these are the dominant cells present. However, we cannot rule out release by other (nonmyocyte) cells obtained in the enzymatic dispersion process. Furthermore, it has been suggested that ET-1 release is activated by ANG II (1, 23) . The present experiments cannot distinguish between this possibility and an in-dependent release of ET-1. The interaction between the two signaling pathways in the regulation of K ϩ currents is obviously complex and will need further investigation. There may also be some basal release from control myocytes, as suggested previously (12) . Blocking ACE or ET-1 receptors in control cells augmented I late , suggesting a tonic suppression of this current. I peak was unaffected, suggesting that only under pathological conditions is this current affected by autocrine mechanisms.
The present work establishs that effects on K ϩ currents, presumably reflecting autocrine release, occur under diverse pathologies. This will impact cardiac electrical activity, because the attenuation of cardiac K ϩ currents will prolong the action potential and potentially contribute to arrhythmogenesis (19, 27) . This could occur by an alteration of repolarization patterns (48) or by appearance of early afterdepolarizatons and indirect changes in calcium influx (37) . Diabetes and hypothyroidism are often accompanied by increased susceptibility to cardiac arrhythmias (5, 13, 15) . Thus the proven benefits to diabetic patients receiving ACE inhibitors (52) may be related to a reduction in cardiac arrhythmias in addition to the alleviation of hypertension, as we suggested earlier (45) . On the basis of present results, the benefits of long-term ET receptor blockade in diabetes (49) may also extend to protection from arrhythmias.
Limitations of study. There are several limitations to this study, although these were considered not to affect the major conclusions. First, it was beyond the scope of the work to directly measure the release of ANG II and ET-1 from the myocytes to establish whether there are true autocrine mechanisms involved. However, such release has been demonstrated previously (1, 11) . The combined use of multiple interventions (saralasin, quinapril, PD142893, and the ECE inhibitor in both diabetic and hypothyroid conditions) strongly supports our working hypothesis and rules out possible nonspecific effects of any one of the agents used. It was beyond the scope of this work to fully analyze changes in other channel proteins. However, the changes measured in Kv4.2 and Kv1.2 strongly support the working hypothesis, whereby ANG II and ET-1 suppress channel protein synthesis. The signals for Kv4.3 were considerably less satisfactory despite the use of two different antibodies and different methods of membrane purification. There was some disadvantage to the Western blotting experiments in that ventricular tissue rather than isolated cells were used. This, however, is common practice (e.g., 36) and was done here to obtain sufficient protein. Although other cell types are abundant in ventricular tissue, the predominant tissue mass is provided by the myocytes. Other cells such as fibroblasts lack Kv4.2. In addition, the parallel changes in I peak and Kv4.2 that were obtained also strongly support our conclusions. A final limitation lies in the fact that no direct evidence was obtained for a maintained pathological subcellular distribution of PKC with DiC8 and the peptide agonists. This too was beyond the scope of the present work, but it should be emphasized that Malhotra et al. (29) showed that ANG II receptor blockers prevented PKC-⑀ redistribution in cardiac cells, consistent with our findings.
